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RESEARCH ARTICLE
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Planar fluorescence imaging is widely used in biological research because of its simplicity, use of nonionizing radiation, and high-throughput data acquisition. In cancer research, where small animal models are used to study the in vivo effects of cancer therapeutics, the output of interest is often the tumor
volume. Unfortunately, inaccuracies in determining tumor volume from surface-weighted projection fluorescence images undermine the data, and alternative physical or conventional tomographic approaches
are prone to error or are tedious for most laboratories. Here, we report a method that uses a priori
knowledge of a tumor xenograft model, a tumor-targeting near infrared probe, and a custom-developed
image analysis planar view tumor volume algorithm (PV-TVA) to estimate tumor volume from planar fluorescence images. Our algorithm processes images obtained using near infrared light for improving imaging depth in tissue in comparison with light in the visible spectrum. We benchmarked our results
against the actual tumor volume obtained from a standard water volume displacement method. Compared with a caliper-based method that has an average deviation from an actual volume of 18%
(204.34 ⫾ 115.35 mm3), our PV-TVA average deviation from the actual volume was 9% (97.24 ⫾
70.45 mm3; P ⬍ .001). Using a normalization-based analysis, we found that bioluminescence imaging
and PV-TVA average deviations from actual volume were 36% and 10%, respectively. The improved
accuracy of tumor volume assessment from planar fluorescence images, rapid data analysis, and the
ease of archiving images for subsequent retrieval and analysis potentially lend our PV-TVA method to
diverse cancer imaging applications.

INTRODUCTION
In recent years, optical imaging has been used with increasing
regularity as an imaging modality. Historically, its primary use
has been in the field of microscopy; however, technological
advances have enabled many applications in small-animal in
vivo imaging (1-3). Compared with conventional imaging modalities such as computed tomography (CT), positron emission
tomography, and magnetic resonance imaging (MRI), optical
imaging of small-animal models can serve as a high-throughput, accurate, low learning curve, and low-cost method for
measuring pathophysiological parameters using nonionizing
radiation. Therefore, thousands of laboratories worldwide have
adopted planar optical imaging as the preferred imaging modality for assessing drug efficacy, developing new molecular imaging probes, and understanding the molecular basis of pathophysiological processes.

In cancer research, molecular probes targeting specific biomarkers have been developed to give insight into tissue-specific
properties (4, 5). These probes allow for the rapid detection of
tumors, assessment of tumor-associated protein expression levels, and evaluating the relative size of tumors. Targeted molecular fluorescence imaging has the potential to improve patient
care by facilitating the understanding of tumor characteristics in
small-animal models. In addition, preclinical testing of new
cancer therapies is often conducted in small-animal models to
determine therapeutic efficacy (2), with tumor volume assessment typically reported as a primary output in interventional
studies.
Preclinical tumor volume is often estimated by measuring
the length and width of a tumor using calipers, and then inputting the values in the equation V ⫽ 0.5 ⫻ L ⫻ W2, where V is the
tumor volume, L is the tumor length, and W is the tumor width.
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This approach is simple, fast, and fairly reliable (6). However, the
potential for user-dependent variability introduces intractable
errors in data analysis (7, 8). When the tumor grows in an
infiltrative manner and invades the underlying tissue, identification of the tumor margin using calipers presents additional
challenges. Moreover, if a measurement is not taken for a given
day, the data cannot be obtained at a later time.
Using fluorescence imaging to determine tumor volume has
been a challenge, largely because of the attenuation of light
within the tissue. For in vivo imaging, light is reflected, scattered, and absorbed as it passes through a heterogeneous medium, thereby obscuring the true boundary of the target object
within the tissue. There are 2 ways to solve the inverse problem
of locating the boundaries of a fluorescent target: mathematically and empirically. Mathematical approaches based on stochastic modeling of light propagation through a medium have
been developed. Further, 3-dimensional quantitative fluorescence imaging has been accomplished by using fluorescence
molecular tomography (FMT) to measure tumor geometry (1, 3).
The drawback of FMT is that it requires a complex setup that is
not accessible to most biological laboratories. In addition, the
process necessary to extract the signal can be computationally
intensive and time consuming, limiting real-time feedback.
Because of the complexity of FMT, planar optical imaging
platforms that use empirical methods have become the hallmark
of most biological imaging studies. Empirical approaches have
been successfully adopted for tumor cell viability testing with
technologies such as bioluminescence imaging (BLI) (9). BLI
projects light generated from the interaction of a bioluminescent
enzyme with its substrate to the animal surface. Because light
emanates spontaneously from cells expressing the bioluminescent protein without the need for external light excitation used
in fluorescence, modern cameras can detect cancer cells with
exceptionally high sensitivity. However, tumor volume measurements obtained from BLI are anecdotal because the method
reports only viability of cells expressing the reporter protein, but
not the actual tumor volume. As tumor cells proliferate, some of
the daughter cells do not express the reporter protein, which
confounds tumor volume assessment.
In this study, we sought to develop a simple optical method for
determining tumor volume from planar fluorescence images. Currently, the inverse problem in tissue optics can be empirically
solved if the target geometry dimensions are known and if parameters to compensate light attenuation are determined. Because
small-animal imaging uses similar tumor models to screen for
therapies, the empirical approach can be used with very few parameters necessary to obtain an adequate fit between the calculated
volume and the actual volume. By using a cancer-targeting molecular probe, we were able to investigate the application of our model
to diverse tumors. Compared with conventional methods, our new
PV-TVA approach is simpler and more accurate. Automation of the
algorithm will increase its potential adoption by current investigators with planar fluorescence imaging systems.
METHODOLOGY
Tumor Models

We used 2 tumor models in this study: HT1080 (human fibrosarcoma) to develop and test the algorithm, and 4T1-Luc (mu18

rine mammary cancer) to compare the algorithm to BLI, which
requires transfected cells. HT1080 xenografts were generated by
administering subcutaneous injection of 3 ⫻ 106 cells into
8-week-old female athymic nude mice in either the right shoulder or the left flank region. The right shoulder region was used
to determine the optimal time point for imaging (n ⫽ 2), and the
left flank region was used for the development of the algorithm
(n ⫽ 3). 4T1-Luc xenografts were generated by administering
subcutaneous injection of 1 ⫻ 106 cells into 6-week-old female
Balb/c mice in the left flank region (n ⫽ 5). The longitudinal
therapeutic study was conducted using the HT1080 flank model
(n ⫽ 4). Tumors were allowed to develop until palpable, and
length and width measurements were taken using calipers. Mice
were anesthetized with isoflurane (3%–5%) during all experimental procedures, including inoculation of tumor cells, caliper
tumor measurement, and image acquisition. All studies were
conducted in compliance with the Washington University Animal Welfare Committee’s requirements for the care and use of
laboratory animals in research.
Fluorescence Imaging Studies

For imaging studies, the mice were injected with a 0.40 mg/kg or
0.80 mg/kg dose of cypate-cGRD, a near infrared (NIR) fluorescent probe (10). This molecular probe is known to target diverse
tumors in vivo. Cypate-cGRD was suspended in 100 L of
Dulbecco’s phosphate buffered saline and injected into the
mouse xenografts through a lateral tail vein injection. Using
excitation and emission wavelengths of 785 and 810 nm, respectively, fluorescence imaging was performed with the Pearl®
Small Animal Imaging System (Li-Cor Biosciences, Inc., Lincoln,
Nebraska). Animals were imaged from a dorsal view at either 0,
1, 4, 24, 48, and 96 hours post injection, or a single image at 24
hours post injection. After the final imaging time point, the mice
were euthanized and the skin was reflected from the tumor
surface. In situ length and width of the tumor were measured
using calipers, and the tumor volume was calculated using the
equation V ⫽ 0.5 ⫻ L ⫻ W2. The tumors were then carefully
excised using the tumor capsule as a guide, and the tumor
volume was measured using a water displacement method.
Grayscale fluorescence images from the 800 nm channel were
output in .jpg format using PearlCam software (Li-Cor Biosciences, Inc.). Image processing and analysis were conducted
via a custom code written in MATLAB (Mathworks, Inc.,
Natick, Massachusetts).
Bioluminescence Imaging Studies

Five 4T1-Luc xenograft mice expressing luciferase received an
intraperitoneal injection of 150 mg/kg D-luciferin in phosphate
buffered saline (Gold Biotechnology, St. Louis, Missouri) for BLI.
Mice were then imaged at 10 minutes under isoflurane anesthesia with IVIS 50 (PerkinElmer, Waltham, Massachusetts; Living
Image 4.3, 1- or 10-second exposures, bin8, field of view 12 cm,
f/stop1 and open filter). The total photon flux (photons/second)
was measured from software-defined contour regions of interest
over the tumors using Living Image 2.6. Bioluminescence from
viable tumor cells was used to estimate tumor burden.
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Figure 1. Color images of a
fluorescent tumor and surrounding tissue with the maximum intensity set to different values (from
left to right): 1.0, 1.5, 2.0, 2.5,
and 3.0 a.u. (A). Grayscale images of the same tumor set to the
same maximum intensity values
as the color images (B). Side and
top images of light scattering in
tissue, with the apparent width of
the source at the top of the finger
(red arrow) larger than the actual width of the light source
(green arrow) (C) and (D). Illustration of a light-emitting fluorescent tumor (light source) within
the scattering medium (E). The
red arrow shows the observed
width at the surface of the tissue, and the green arrow shows
the actual width of the tumor
within the surrounding tissue.

Longitudinal Therapeutic Studies

One of the benefits of using the PV-TVA to measure the tumor
volume is to determine the efficacy of therapy over time. To
investigate the treatment response, we obtained longitudinal
images using an HT1080 xenograft model. Four mice were
injected with a 0.40 mg/kg dose of cypate-cGRD via the tail
vein, once a week for 4 weeks. In 2 of the mice, doxorubicin was
administered at a dose of 10 mg/kg after a baseline image was
obtained. The doxorubicin was dissolved in dimethyl sulfoxide,
and then mixed in Dulbecco’s phosphate buffered saline to
obtain the desired dose in 100 L of solution.
RESULTS
Algorithm Development

To calculate the tumor volume from planar images, we first
determined a suitable fluorescent probe to use and the proper
time point to image. We selected cypate-cGRD because of its
versatility in targeting a number of different tumor types. We
then determined the optimal time point to analyze the images.
The fluorescent probe was injected into the tail vein of each
mouse bearing HT1080 tumors. Imaging was performed at multiple time points post injection using Pearl Small Animal Imaging System (Supplemental Figure 1A). We compared the tumor
region to an equivalently sized nontumor region. The maximum
difference of the fluorescence signal from the tumor compared
with that from the nontumor region was obtained at 24 hours
post injection (Supplemental Figure 1B), exhibiting the maximum tumor-to-nontumor ratio (Supplemental Figure 1C), and
optimal imaging time point.
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The next step was to determine the proper type of image to
analyze. The Pearl Small Animal Imaging System has the ability
to create images using a color map, grayscale, and numerous
other visualization options. The color map image provides for a
rapid method to visualize tumor contrast from the surrounding
tissue; however, slight changes in the intensity scale may produce significant changes in the apparent tumor outline (Figure
1A). Color images rely on the user’s visual interpretation to
create the best guess for how to threshold the tumor boundary,
therefore leading to variability. A more reliable approach is to
reduce the need for perceptive input from the user. When analyzed, grayscale images produced a consistent tumor region as
the contrast settings were varied (Figure 1B). To further standardize the approach, the grayscale images for output were
selected by increasing the maximum intensity in the image until
just below the point where the image became saturated. This
technique allowed for maximum contrast between the signal
and background without losing information in the image.
Despite the consistent tumor image produced by using grayscale, the light attenuation due to tissue scattering remained a
confounding factor in determining the true tumor outline. This is
similar to what is observed in Figure 1, C and D, where the light
source is smaller than the observed light after it passes through the
tissue. Image processing allows for an algorithm to account for the
amount of scattering for a given tissue system. Because xenograft
models of a particular tumor type are relatively consistent, the
parameters to account for scattering can be set for all other samples
once they are known for a given tumor model.
19
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Figure 2. Input image with an illustrated user-selected line for region of interest identification (A). Intensity profile along
the line (pink curve) with a Threshold value (green dashed line) (B). Moving slope (blue lines) of the intensity profile calculated along the line (C). Plot of the moving slopes (blue points) calculated along the line, with the inflection points of
the intensity (red points) (D). Two inflection points identified (red points) and the average used for the tumor boundary
determination (red line) (E). Algorithm-determined tumor outline overlaid on the image without using the Threshold value
(F). Algorithm-determined tumor outline overlaid on image using the Threshold value to account for scattering (G). Tumor
length (blue solid line) and tumor width (cyan dashed line) overlaid on image (H).

To initiate the PV-TVA, 2 points were selected by the user
approximately along the horizontal axis of the tumor from the
grayscale image. This line was long enough to go from uninvolved tissue, through the tumor, and back to the uninvolved
tissue (Figure 2A). An intensity curve was created using the
intensity values from the pixels along the length of the line
(Figure 2B). The slope of the intensity curve was calculated for
each point along the line using the subsequent number of pixels
that the user specified (user-input parameter; Figure 2C). The use
of a larger number of pixels to calculate the slope acted as a
smoothing operation, making the algorithm less sensitive to
local variability. Once the slopes were calculated along the
length of the line, the maximum and minimum slope values
were identified as the inflection points of the intensity plot
along the line (Figure 2D). The average of these intensity values
was used to determine the average value of the edge of intensity
observed at the surface of the skin (Figure 2E). All values above
this intensity were found within the user-selected region (Figure
2F). Once this procedure was completed, it became evident that
the scattered light caused the apparent tumor outline to be larger
than the actual tumor outline, as was later verified using postmortem in situ measurements.
To account for this variability, a threshold value was created
to decrease the outline of the tumor with the verified assumption
that the scattered light contributes to increasing the imaged
tumor outline dimensions. For example, a Threshold value of
0.25 would select the highest 25% of values that were along the
user-selected line and calculate the inflection points based on
only those values. Once the threshold was determined, the slopes
of the intensity values were calculated using only the values that
fell above that threshold value (Figure 2C). Adding a Threshold
20

parameter to the PV-TVA resulted in a more accurate identification of the tumor from the images (Figure 2G).
The threshold was defined in Equation 1 as:
Threshold ⫽ Imax ⫺ Percent(Imax ⫺ Iavg),

(1)

Where Threshold is the minimum intensity value accepted as
potentially originating from the tumor tissue, Imax is the maximum intensity value originating from the mouse, Iavg is the
average intensity value for the mouse, and Percent is a userinput value specific to the system being analyzed.
Percent was chosen as the user-input value rather than
Threshold because inputting the Percent parameter allowed the
incorporation of the intensity contrast between the tumor and
the surrounding tissue for determining the threshold value. This
approach balanced the need for tuning the threshold based on
the system properties (the tumor morphological appearance, dye
kinetics, and dye attenuation properties at the emission wavelength), with preserving the relationship of the tumor contrast
within the image. By changing the Percent value, this tunable
threshold allowed for versatility of the algorithm for different
biological systems and dye concentrations. The Percent value was
initially determined by using the postmortem tumor volume value
from one mouse, and then that value was subsequently used to
analyze the images for all the following mice. This Percent value
was validated after the study by running the PV-TVA at various
Percent values, and comparing each resultant tumor volume to the
actual value (Figure 3E). The validation confirmed that the initially
selected Percent was valid for all of the tumors of this type. Future
study will explore the use of a receiver operating characteristic
curve to estimate the optimal threshold per fluorescent imaging
agent. This value will be input into the algorithm.
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Figure 3. Tumor volumes for 3 HT1080 tumors (T1, T2, and T3) as determined using the caliper measurement method
for 2 users (C-U1 and C-U2), and the planar view tumor volume algorithm (PV-TVA) (Percent ⫽ 0.55) (A). Tumor volume
calculation deviations from the actual volume as measured using postresection water displacement (B). Absolute value of
the deviations of the tumor volume calculation methods to measure the accuracy (C). Average standard deviations of 10
measurements for each of the 3 tumors to measure the precision (D). Validation for the Percent value selected to calculate tumor volume (E). *P ⱕ .05, **P ⱕ .01, and ***P ⱕ .001.

The final tumor volume was calculated by determining the
length and width of the outlined tumor (Figure 2H). The length was
defined as the longest distance between 2 points on the outline. The
width was defined as the distance between the 2 points, on opposite
sides of the line defining the length, with the maximum perpendicular distance from the line defining the length. The volume was
calculated using the same equation as that in the caliper method.
There was a tradeoff between versatility and variability
when conducting automated image analysis. Therefore, the PVTVA had some inherent variability based on the initial 2 points
that the user selected. Allowing the user to select the initial 2
points facilitated independent analysis of multiple tumors on
the same mouse, and it was therefore an essential part of the
algorithm. The potential variability from this was compared
with the variability in the tumor volume caliper measurement
method. The PV-TVA was run 10 times for a given set of images,
with the user selecting different input points, to understand the
precision and accuracy of the calculated values. The tumors
were measured using calipers 10 times by 2 users who were
blinded to the previous readings to capture the inherent variation in measurements using calipers.
Tumor Volume Calculations

Three HT1080 tumors were analyzed to test the capabilities of
the PV-TVA. We used caliper measurements as our control, and
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then blinded the user to the previous caliper measurement. To
capture inter-user variability, 2 users measured each tumor 5
times, for a total of 10 measurements. Figure 3A shows the
caliper-measured tumor volumes separated by the user. T1 and
T3 produced similar results; however, T2 showed a difference in
caliper-calculated volume between users (P ⫽ .010). We binned
the caliper measurements of both users for each tumor and
repeated the PV-TVA 10 times for each tumor. The results were
compared with the actual tumor volume obtained from the
volume of water displaced by the tumor, and the deviations from
the calculated versus actual tumor volume were compared for
the caliper method and the PV-TVA method (Figure 3B). The
accuracy of each method was assessed by calculating the average of the absolute value of the deviations for the caliper and
PV-TVA methods. The caliper average deviation was 18%
(204.34 ⫾ 115.35 mm3) and the PV-TVA average deviation was
9% (97.24 ⫾ 70.45 mm3; P ⬍ .001; Figure 3C). A comparison of
the precision of each method using the standard deviations of
the 10 calculations showed that the average standard deviations
were 11% (131.95 mm3) and 8% (96.51 mm3) for the caliper and
the PV-TVA methods, respectively (Figure 3D).
The in situ length and width were measured by reflecting
the skin and measuring the tumor before complete resection. Our
result showed that the absolute value of the length deviations
21
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Figure 4. BLI images for 5 4T1-Luc tumors (T1, T2, T3, T4, and T5) (A). Normalized tumor burden values for the actual
volume, caliper, BLI, and the PV-TVA (B). All measurements were normalized to the T1 value for the specific type of measurement. The PV-TVA result was obtained using Percent ⫽ 0.25. Normalized tumor volume deviation from actual as a
percentage of T1 for each method (C). Tumor volume percent deviation from the actual for the caliper and PV-TVA methods (D). Validation for the Percent value selected to calculate tumor volume using postmortem tumor volumes (E). The
tumor volume deviations were calculated at various Percent values for the 4T1-Luc tumor model.

from the in situ dimensions were, on average, 10% (1.21 ⫾ 0.44
mm) for the calipers and 5% (0.68 ⫾ 0.21 mm) for the PV-TVA
(P ⬍ .001; Supplemental Figure 2, A and B) methods. The
absolute value of the width deviations was, on average, 8% (0.81
⫾ 0.48 mm) for the calipers and 5% (0.55 ⫾ 0.31 mm) for the
PV-TVA (P ⫽ .001; Supplemental Figure 2C) methods.
We next examined how this algorithm compared with other
planar optical methods for determining tumor burden. BLI was
conducted on a set of 4T1-Luc tumors, and the results were
compared with those of the caliper and PV-TVA methods. Because BLI does not give the tumor volume, the measurements for
5 tumors were all normalized to the value of the first tumor (T1).
This analysis allowed us to compare the trend in tumor burden
between the different tumors. The same normalization to T1 was
done using the actual tumor volumes as measured by the water
displacement method and for the caliper and PV-TVA methods.
The analysis revealed that the BLI measurements had a similar
trend to the actual tumor volumes (Figure 4B), except for the
case of T3 where the BLI would have predicted a much smaller
tumor than what was observed (Figure 4A). In this case, the
PV-TVA predicted a similar burden as the ground truth measurement obtained using the water displacement method. The
deviations of each normalized value from the actual normalized
value were calculated for the BLI, caliper, and PV-TVA methods
(Figure 4C). When comparing the deviations, BLI, caliper, and the
PV-TVA methods had absolute value average deviations of 36% of
T1, 19% of T1, and 10% of T1, respectively. Normalization for
22

comparative analysis allowed for the comparison of trends, but it
did not give insight into the absolute deviations without extrapolation. Figure 4D shows the signed deviation from the actual deviation for the caliper and the PV-TVA methods. The average absolute value of the deviations was 37% (112.9 ⫾ 93.62 mm3) for the
calipers and 18% (60.52 ⫾ 62.65 mm3) for the PV-TVA (P ⫽ .105)
methods. The Percent value for this tumor model was 0.25. The
PV-TVA was run at various Percent values and compared with the
actual volume for validation (Figure 4E).
To assess the ability of the PV-TVA to monitor the tumor
response to a given treatment, we used the HT1080 tumor model
because it has previously shown a treatment response to doxorubicin. We took a baseline NIR image of each of the mice to
establish the pretreatment tumor volume. Two of the mice were
treated with doxorubicin, and all of the mice were followed for
additional 3 weeks. The NIR images show the range of tumorto-background signals obtained using planar fluorescence imaging (Figure 5A). Because the PV-TVA calculates a threshold
based on a combination of a user-input Percent value and the
inherent image contrast, the PV-TVA could calculate the tumor
volume, despite the varied appearance of the images, in all but 1
of the images (T4-week 2). Regarding the image that did not
produce a solution, there was insufficient contrast at the location of the tumor to calculate the tumor volume. To account for
various initial tumor volumes at the time of treatment, the tumor
response was calculated as a percentage of the pretreatment
volume. At each time point, the PV-TVA was run 3 times. The
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Figure 5. NIR images of four HT1080 mice, with the left-flank tumors (T1, T2, T3, and T4) indicated by the arrows (A).
Each mouse was imaged once a week for 4 weeks. Images had different tumor signals, average mouse signals, and
tumor-to-mouse contrast. Tumor volumes, over time, normalized to the pretreatment volume. Doxorubicin-treated mice
(dashed line) showed suppressed tumor growth compared with the control mice following the administered dose (white
arrow) (B). Validation for the Percent value used in the HT1080 longitudinal treatment study after multiple fluorophore
injections over time (Percent ⫽ 0.55) (C).

doxorubicin-treated mice showed a tumor-growth suppression
over time when compared with the control mice (Figure 5B). This
result was obtained even when image properties such as tumor
signal and average mouse signal varied (Supplemental Figure 3).
We also confirmed that the Percent value used to calculate
tumor volume did not change because of multiple fluorophore
injections. The PV-TVA was run at the final time point (4th
fluorophore injection), for various Percent values, to confirm
that the original HT1080 Percent value remained valid (Figure
5C). A Percent value of 0.55 produced the smallest deviation
from the actual value, consistent with the single time point
study using an HT1080 tumor model (Figure 3E).
DISCUSSION
When determining the tumor volume, calipers are cost-effective
and relatively straightforward. However, they introduce variability that is in excess of what we observed from our PV-TVA
data. Using an algorithm-based approach minimizes the userinduced measurement variability. The PV-TVA works by allowing the user to input a fluorescence image, converting the image
to a matrix of grayscale values, using user-selected points to
determine the region of interest, and then using a gradientbased calculation to calculate the tumor volume (Figure 6).
The gradient-based calculation accounts for light scattering
of fluorescence in a given system, allowing the algorithm to
select the apparent tumor outline in a number of different
systems. By combining the inherent image properties, along
with a user-input parameter, the tumor volume can be reproducibly calculated.
The user-input value, Percent, can be determined for different
systems by acquiring empirical data. The Percent value used for the
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group of 4T1-Luc tumors in Figure 4 was different than the value
used in the HT1080 group of tumors in Figure 3. It is important to
note that the injected fluorescent probe concentration also differed
among the groups. This emphasizes the versatility of the PV-TVA,
along with the importance of calibration for a given system, for
obtaining the ideal Percent value. Once this parameter is obtained,
the value can be used on subsequent images that satisfy the same
conditions. Moreover, we showed that this parameter remains consistent even after multiple fluorophore injections.
In addition to reducing variability, using an imaging approach
has other advantages. Obtaining an image over a direct measurement
allows for retrospective analysis and calculations to be made after the
study has been completed. The PV-TVA can be used with any targeted
fluorescent probe with enhanced signal within the tumor, making it
highly versatile. Our current method is optimized for images using NIR
fluorescence, which provides a larger gradient in the intensity of the
surface-weighted projection fluorescence image, allowing for more
extensive fine-tuning of the volume calculation. The ability to interrogate deeper tissues with NIR light, from diverse NIR fluorescent
molecular probes and proteins, creates an opportunity to apply the
PV-TVA method in data analysis for many studies. Because the PVTVA relies on the gradient of the fluorescent signal, any image with an
adequate contrast between the tumor and the surrounding tissue could
use this approach to determine the tumor volume. Thus, the method
can be extended to visible light images with adequate tumor-tobackground contrast. A recalibration of the algorithm would be required to optimize the PV-TVA for use in the visible range, which can
be accomplished in future studies.
A goal of this study is to provide a rapid and retrievable
quantitative analysis using planar fluorescence images. We illus23
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Figure 6. Planar view tumor volume algorithm (PV-TVA) schematic. The user inputs the image
and the Percent value, and then
selects 2 points on the opposite
sides of the tumor. The algorithm
then calculates the tumor volume
based on the gradient along the
line connecting the 2 points that
the user selected.

trated the application of the PV-TVA in subcutaneous tumor models because these models are extensively used in cancer research.
For deep tumors, the algorithm could be calibrated for a type of
tumor with a known depth. However, if the depth varied for a type
of tumor model, additional a priori information from other sources
such as CT or MRI would be required to develop a reliable metric for
the PV-TVA. A similar challenge is applicable to metastatic tumors
in deep tissues, but our method can longitudinally track the volume
of subcutaneous tumor metastases, providing additional insights
into tumor progression. Because of the large signal variability of
deep tumors and metastasis, a more complex algorithm would be
required, which is outside the scope of the current study.
The PV-TVA performed as well as, or better than, the BLI. The
luciferin injection for BLI can be a variable factor in determining the
resultant signal. This variability was evident in tumor T3 (Figure 4),
where the tumor visibly appeared to be larger than the others, but only
a small BLI signal was obtained. Several factors could mediate this
observation, including an inadequate injection of the substrate, a
reduced cellular division rate, cellular mutations, or other biologic
variables. In contrast, a fluorescent probe can be used in nontransfected cells, thereby reducing much of this biological variability. For
longitudinal studies, the fluorescent probe can be reinjected at subsequent time points to track the response of tumors to therapy. The
longitudinal study was executed using a modified code that used a
center-point slope calculation, rather than a forward-stepping slope
calculation. Both methods produced similar results, which provide
flexibility to the user in selecting the best logic for a given application.
Future studies will focus on improving some of the limitations of our approach. Occasionally, the algorithm selected an
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incorrect tumor width. The current algorithm provides the user
with visual feedback of the width points identified. Although the
width of an object is relatively apparent to the operator, designing an algorithmic logic to select the desired dimension on
irregular shapes is desirable, but complex. A more robust approach for selecting tumor width will be examined in future
revisions. After optimizing the logic for the final code, the
algorithm will be benchmarked against additional imaging modalities such as CT, MRI, FMT, and multimodal imaging.
In summary, the fluorescent guided PV-TVA provides an
alternative to physically measuring tumor volumes using calipers, other empirical optical methods such as BLI, or other
optical methods such as FMT. An initial calibration study is
needed for a given system before the PV-TVA can be run on
subsequent images without any additional a priori information.
The ability to measure tumor volume in a noninvasive, costeffective manner is beneficial for rapid determination of this
important parameter, particularly when retrospective analysis is
desired. In combination with tumor-targeted molecular probes,
our approach allows for accurate determination of tumor volumes without any additional action by the user.
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